"Tenofovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
| Descriptor ID |
D000068698
|
| MeSH Number(s) |
D02.705.429.906 D03.633.100.759.138.881
|
| Concept/Terms |
Tenofovir- Tenofovir
- 9-(2-Phosphonylmethoxypropyl)adenine
- 9-PMPA (tenofovir)
- 9-(2-Phosphonomethoxypropyl)adenine
|
Below are MeSH descriptors whose meaning is more general than "Tenofovir".
Below are MeSH descriptors whose meaning is more specific than "Tenofovir".
This graph shows the total number of publications written about "Tenofovir" by people in this website by year, and whether "Tenofovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 5 | 5 |
| 2016 | 2 | 3 | 5 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 2 | 6 |
| 2019 | 3 | 3 | 6 |
| 2020 | 3 | 3 | 6 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 4 | 5 |
| 2024 | 5 | 7 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tenofovir" by people in Profiles.
-
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
-
The impact of HIV infection on skeletal maturity in peripubertal children in Zimbabwe: a cross-sectional study. BMC Pediatr. 2024 Jul 27; 24(1):480.
-
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268.
-
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. Clin Infect Dis. 2024 Jun 14; 78(6):1617-1628.
-
Oral preexposure prophylaxis uptake, adherence, and persistence during periconception periods among women in South Africa. AIDS. 2024 07 15; 38(9):1342-1354.
-
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
-
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024 Jul; 25(7):826-839.
-
Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.